[Federal Register Volume 78, Number 207 (Friday, October 25, 2013)]
[Notices]
[Page 64018]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-25079]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application, 
Nektar Therapeutics

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 16, 2013, Nektar 
Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Fentanyl (9801), a basic class 
of controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
support of product development.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODW), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than December 24, 2013.

     Dated: September 27, 2013.
 Joseph T. Rannazzisi,
 Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-25079 Filed 10-24-13; 8:45 am]
BILLING CODE 4410-09-P